Recent advances in the understanding and management of mucormycosis

Benoit Pilmis; Alexandre Alanio; Olivier Lortholary; Fanny Lanternier

doi:10.12688/f1000research.15081.1

Recent advances in the understanding and management of mucormycosis

F1000Res. 2018 Sep 7:7:F1000 Faculty Rev-1429. doi: 10.12688/f1000research.15081.1. eCollection 2018.

Authors

Benoit Pilmis^{1

2}, Alexandre Alanio^{3

4

5}, Olivier Lortholary^{1

4

5}, Fanny Lanternier^{1

4

5}

Affiliations

¹ Paris Descartes University, Sorbonne Paris Cité, Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Imagine Institute, Paris, France.
² Antimicrobial Stewardship Team, Microbiology Unit, Groupe Hospitalier Paris Saint Joseph, Paris, France.
³ Université Paris Diderot, Sorbonne Paris Cité, Laboratoire de Parasitologie-Mycologie, Hôpital Saint-Louis, Groupe Hospitalier Lariboisière, Saint-Louis, Fernand Widal, AP-HP, Paris, France.
⁴ Molecular Mycology Unit, Institut Pasteur, CNRS UMR2000, Paris, France.
⁵ Centre National de Référence Mycoses invasives et Antifongiques, Institut Pasteur, Paris, France.

Abstract

Mucormycoses were difficult-to-manage infections owing to limited diagnostic tools and therapeutic options. We review here advances in pathology understanding, diagnostic tools including computed tomography, and serum polymerase chain reaction and therapeutic options.

Keywords: Isavuconazole; Liposomal amphotericin B; Mucormycosis; PCR; Reverse Halo sign.

Publication types

Review

MeSH terms

Animals
Antifungal Agents / therapeutic use
Humans
Mucormycosis / diagnosis
Mucormycosis / pathology
Mucormycosis / therapy*
Polymerase Chain Reaction
Tomography, X-Ray Computed

Substances

Antifungal Agents

Grants and funding

The author(s) declared that no grants were involved in supporting this work.